Cantor Fitzgerald Reiterates Overweight on Disc Medicine, Raises Price Target to $65
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Kristen Kluska reiterated an Overweight rating on Disc Medicine (NASDAQ:IRON) and raised the price target from $45 to $65.
June 09, 2023 | 5:42 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald analyst Kristen Kluska reiterated an Overweight rating on Disc Medicine and raised the price target from $45 to $65.
The reiteration of an Overweight rating and an increased price target by a reputable analyst like Kristen Kluska from Cantor Fitzgerald is a positive signal for Disc Medicine. This news is likely to boost investor confidence and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100